Investor Relations
Investment
opportunity
MAI Medical USA distributes FDA-cleared neurostimulation devices addressing large, underserved markets in pain management and withdrawal treatment.
Market Opportunity
A growing need for
drug-free alternatives
37M+
Americans living with diabetes. Up to 50% develop neuropathy.
100K+
Annual overdose deaths. Withdrawal barriers prevent treatment entry.
Millions
Adolescents affected by IBS. Limited non-drug options available.
Statistics from CDC, NIH, and published epidemiological research.
Our Portfolio
4 FDA-cleared devices,
4 clinical indications
K212859
NeuMona
Diabetic Neuropathy
DEN180057
GiCalm
IBS Abdominal Pain
K221425
NociRelief
Post-Surgical Pain
DEN170018
OpiEase
Opioid Withdrawal
Business Model
US distribution of
proven technology
MAI Medical USA is the authorized US distributor for independently branded, FDA-cleared neurostimulation devices developed in Switzerland. Our model: source proven devices, train US providers, support patient access, and scale nationwide.